Cardiol Therapeutics Current Valuation vs. Number Of Shares Shorted
| CRDL Stock | USD 1.33 0.03 2.21% |
For Cardiol Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cardiol Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cardiol Therapeutics Class utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cardiol Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cardiol Therapeutics Class over time as well as its relative position and ranking within its peers.
Cardiol |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cardiol Therapeutics. If investors know Cardiol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cardiol Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Return On Assets (0.54) | Return On Equity (1.08) |
The market value of Cardiol Therapeutics is measured differently than its book value, which is the value of Cardiol that is recorded on the company's balance sheet. Investors also form their own opinion of Cardiol Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cardiol Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cardiol Therapeutics' market value can be influenced by many factors that don't directly affect Cardiol Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cardiol Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cardiol Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cardiol Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cardiol Therapeutics Number Of Shares Shorted vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cardiol Therapeutics's current stock value. Our valuation model uses many indicators to compare Cardiol Therapeutics value to that of its competitors to determine the firm's financial worth. Cardiol Therapeutics Class is the top company in current valuation category among its peers. It also is number one stock in number of shares shorted category among its peers making about 0.01 of Number Of Shares Shorted per Current Valuation. The ratio of Current Valuation to Number Of Shares Shorted for Cardiol Therapeutics Class is roughly 86.04 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Cardiol Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Cardiol Current Valuation vs. Competition
Cardiol Therapeutics Class is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 156.62 Million. Cardiol Therapeutics totals roughly 97.41 Million in current valuation claiming about 62% of equities under Health Care industry.
Cardiol Number Of Shares Shorted vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cardiol Therapeutics |
| = | 97.41 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Cardiol Therapeutics |
| = | 1.13 M |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Cardiol Number Of Shares Shorted Comparison
Cardiol Therapeutics is currently under evaluation in number of shares shorted category among its peers.
Cardiol Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cardiol Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cardiol Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Cardiol Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Cardiol Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 4 M | 3.8 M | |
| Net Interest Income | 2.2 M | 2.3 M | |
| Interest Income | 2.2 M | 2.3 M | |
| Operating Income | -29.8 M | -31.3 M | |
| Net Loss | -28 M | -29.4 M | |
| Income Before Tax | -28.1 M | -29.5 M | |
| Total Other Income Expense Net | 1.7 M | 1.8 M | |
| Net Loss | -27.8 M | -29.2 M | |
| Net Loss | -28.1 K | -29.5 K | |
| Income Tax Expense | 5.00 | 5.25 | |
| Change To Netincome | -2 M | -1.9 M | |
| Net Loss | (0.44) | (0.46) | |
| Net Income Per E B T | 0.43 | 0.41 |
Cardiol Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cardiol Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cardiol Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cardiol Therapeutics' important profitability drivers and their relationship over time.
Use Cardiol Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cardiol Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cardiol Therapeutics will appreciate offsetting losses from the drop in the long position's value.Cardiol Therapeutics Pair Trading
Cardiol Therapeutics Class Pair Trading Analysis
The ability to find closely correlated positions to Cardiol Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cardiol Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cardiol Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cardiol Therapeutics Class to buy it.
The correlation of Cardiol Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cardiol Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cardiol Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cardiol Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cardiol Therapeutics position
In addition to having Cardiol Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Machinery Thematic Idea Now
Machinery
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Machinery theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Machinery Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
To fully project Cardiol Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cardiol Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cardiol Therapeutics' income statement, its balance sheet, and the statement of cash flows.